European Alliance

Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 11, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, U.S. Securities and Exchange Commission, ASCO, AbbVie, Cancer, Investment, Leadership, APRIL, Security (finance), Research, Renal cell carcinoma, Pembrolizumab, Securities Act of 1933, Securities Exchange Act of 1934, BAFF, Federal Lands Jobs and Energy Security Act, Industry, American Society of Clinical Oncology, Technology, Annual general meeting, Private Securities Litigation Reform Act, Autoimmunity, Protein engineering, European Alliance, Congress, Merck, Horizon Therapeutics, Merck & Co., Safety, Doctor of Philosophy, Nature, Combination therapy, SLE, Forward-looking statement, COVID-19, Acquisition, FDA, NEON, Inflammation, EULAR, ALPN, Society, Review, Company, Twitter, NASDAQ, LinkedIn, Pharmaceutical industry, MD, Rheumatology, Alpine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2022.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2022.
  • Collaboration revenue for the second quarter ended June 30, 2022 was $5.3 million compared to $7.2 million for the second quarter ended June 30, 2021.
  • General and administrative expenses for the second quarter ended June 30, 2022 were $4.2 million compared to $3.3 million for the second quarter ended June 30, 2021.
  • NEON-1, NEON-2, "Synergy, RUBY, and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.

Dyve Biosciences Announces Phase 2 TARGETS Study of DYV702 for Pain Associated with Acute Gout Flares Showcased in Podium Presentation at 2022 EULAR Congress

Retrieved on: 
Wednesday, June 1, 2022
European Alliance, Pain, Congress, EULAR, Steroid, Gout, Toxicity, Sodium bicarbonate, PROMIS, University, MI, Nonsteroidal anti-inflammatory drug, GLOBE, Patient, Population, Hospital, MPH, Colchicine, Swelling, Pharmaceutical industry, Medical imaging, Rheumatology

Dr. Khanna commented, There remains a dearth of effective, approved treatments to relieve the intense debilitating pain that accompanies acute gout flares.

Key Points: 
  • Dr. Khanna commented, There remains a dearth of effective, approved treatments to relieve the intense debilitating pain that accompanies acute gout flares.
  • Hospital admissions for acute gout flares have doubled in the U.S. over the past two decades.
  • Current options like steroids, colchicine, NSAIDs and IL-1 inhibitors are antiquated and non-selective, which results in significant toxicity and frequent drug-drug interactions.
  • DYV702 showed significant improvement in PROMIS PF-20 scores at 24 hours, with 16.7 for DYV702 vs. 9.4 for control (p

Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

Retrieved on: 
Friday, June 3, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, European Alliance, Congress, EULAR, Company, Lupus nephritis, SLE, MMF, European Renal Association – European Dialysis and Transplant Association, Proteinuria, ERA, Nephrology, Therapy, University, LMU, Patient, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Autoimmune disease, NASDAQ, Pharmaceutical industry, Aurinia, UPCR, Rheumatology

A treatment response meeting these proteinuria treatment targets increases the chance for better long-term kidney outcomes such as avoidance of kidney failure, dialysis or need for transplantation.

Key Points: 
  • A treatment response meeting these proteinuria treatment targets increases the chance for better long-term kidney outcomes such as avoidance of kidney failure, dialysis or need for transplantation.
  • LUPKYNIS is the first FDA-approved oral medicine for the treatment of adult patients with active lupus nephritis (LN).
  • In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN).
  • QTc Prolongation: LUPKYNIS prolongs the QTc interval in a dose-dependent manner when dosed higher than the recommended lupus nephritis therapeutic dose.

Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

Retrieved on: 
Wednesday, June 1, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, European Alliance, Degenerative disease, Congress, Adult, EULAR, Lupus, Immunization, Securities Exchange Act of 1934, Survival, Doctor of Philosophy, Western literature, Securities Act of 1933, SLE, LinkedIn, Private Securities Litigation Reform Act, Animal, Pharmacokinetics, Inflammation, Forward-looking statement, Nature, Security (finance), Protein engineering, U.S. Securities and Exchange Commission, B-cell activating factor, BAFF, Immunoglobulin G, Volunteering, Immunoglobulin A, Autoimmunity, ID, Development, Patient, Technology, Immunoglobulin M, Alpine, COVID-19, NASDAQ, MD, Twitter, Cytokine, TACI, ALPN, Cancer, Safety, Vaccine, Pharmaceutical industry, Research, Human, Rheumatology

ALPN-303 is an Fc fusion of an engineered TACI domain that has significantly improved affinity against the B cell cytokines BAFF and APRIL -- particularly the latter, which wild-type TACI-Fc binds inferiorly. Correspondingly superior pharmacokinetics were observed in animals, as well as pharmacological activity in mouse models of immunization and lupus. Preliminary findings in early single dose cohorts of adult healthy volunteers demonstrate dose-dependent reductions in circulating immunoglobulins (IgA, IgG, IgM).

Key Points: 
  • ALPN-303 is being developed for systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases.
  • Correspondingly superior pharmacokinetics were observed in animals, as well as pharmacological activity in mouse models of immunization and lupus.
  • Preliminary findings in early single dose cohorts of adult healthy volunteers demonstrate dose-dependent reductions in circulating immunoglobulins (IgA, IgG, IgM).
  • This is of particular importance as we endeavor to surmount challenging target diseases such as lupus and other B-cell related inflammatory diseases.

CreakyJoints Data Shows that Social Determinants of Health Bias Patient Satisfaction Scores in the Hispanic Community

Retrieved on: 
Wednesday, June 1, 2022
Technology, Mobile, Wireless, Research, Clinical Trials, Software, Health, General Health, Data Management, Science, Life, European Alliance, EULAR, Arthritis, Research, Doctor of Philosophy, RA, Bias, Conditional sentence, Disease, Patient satisfaction, Physician, Patient, PPQ, Reuters, Rheumatoid arthritis, Focus, MD, Lists of diseases, Osteoarthritis, Medical Affairs Bureau, Flare, RMD, Smartphone, Axial spondyloarthritis, Medicine, Medical device, Rheumatology

Do Patient and Physician Assessments of a Health Care Visit Match for Hispanic/Latinx Patients with Rheumatoid Arthritis in the United States and Puerto Rico?

Key Points: 
  • Do Patient and Physician Assessments of a Health Care Visit Match for Hispanic/Latinx Patients with Rheumatoid Arthritis in the United States and Puerto Rico?
  • The survey was made available on tablet devices in four rheumatology clinics in the U.S. and Puerto Rico.
  • Then, a survey (n=570) with the final 28 items was administered via CreakyJoints ArthritisPower Research Registry in January 2022.
  • During the development phase, CreakyJoints interviewed users and then conducted confirmatory market research to ensure that planned enhancements met the needs of the CreakyJoints community.

Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Nature Communications, Company, Autoimmunity, Protein engineering, Private Securities Litigation Reform Act, Research, U.S. Securities and Exchange Commission, CD28, AbbVie, Poster, SLE, Merck & Co., AACR, NASDAQ, Investment, EULAR, Nature, Association, COVID-19, NEON, Merck, BAFF, Securities Act of 1933, Pembrolizumab, Securities Exchange Act of 1934, Forward-looking statement, European Alliance, Congress, Technology, Safety, Federal Lands Jobs and Energy Security Act, ALPN, LinkedIn, Inflammation, American Association, Twitter, Security (finance), Combination therapy, Cancer, MD, Pharmaceutical industry, Video game, Rheumatology, Horizon, Alpine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.
  • Collaboration revenue for the first quarter ended March 31, 2022 was $13.6 million compared to $3.2 million for the first quarter ended March 31, 2021.
  • Alpine Immune Sciences is committed to leading a new wave of immune therapeutics.
  • NEON-1, NEON-2, "Synergy," and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.

European Commission Approves JUST Egg's Key Ingredient as Plant-Based Brand Plans Fourth Quarter Launch

Retrieved on: 
Tuesday, April 5, 2022
Supermarket, Retail, Other Retail, Food, Beverage, Innova, European Parliament, European Food Safety Authority, EFSA, The Good Food Institute, ProVeg International, Council Implementing Regulation (EU) No. 282/2011, Climate change, Multimedia, Public health, European Free Trade Association, European Commission, Gesellschaft mit beschränkter Haftung, Commission, Research, Forest Law Enforcement and Governance Program, Plant, Food technology, CEO, European Alliance for Innovation, Health, Meat, Council, Egg, Protein, Royal commission, Association, Technology, University of Copenhagen Faculty of Science, Copenhagen, Ghent University, Just!, European Alliance, Union, Animal, WIRED, Eat Just, University, Partnership, Legume, Poultry, Online shopping, Guardian, European, Nielsen

The landmark approval for mung bean protein paves the way for the launch of JUST Egg in Europe in the fourth quarter of this year.

Key Points: 
  • The landmark approval for mung bean protein paves the way for the launch of JUST Egg in Europe in the fourth quarter of this year.
  • (Photo: Business Wire)
    This decision means Americas fastest-growing egg brand can enter the market in countries belonging to the European Union and the European Free Trade Association.
  • Forward-thinking consumers in Europe have been asking for JUST Egg since the day it launched in the U.S.
  • The Commissions action is based upon the European Food Safety Authoritys (EFSA) earlier determination that mung bean protein is safe under novel food requirements.

Researchers Find Lower Risk of Severe COVID-19 Infection in Most Children with Juvenile Idiopathic Arthritis

Retrieved on: 
Thursday, March 31, 2022
Hospital, Risk, Face, University, Annals of the Rheumatic Diseases, Arthritis, Arthritis Foundation, Obesity, JIA, Childhood arthritis, Diagnosis, Death, Multimedia, Association, Research, Vasculitis, Juvenile idiopathic arthritis, Patient, Body mass index, Pediatrics, Data analysis, Lists of diseases, Joint, Immune system, TNF, Lupus, COVID-19, Harvard Medical School, European Alliance, EULAR, Rheumatism, News, COVID, University of Manchester, Pharmaceutical industry, Animal, Boston Children's Hospital, Rheumatology

The findings, published in the Annals of the Rheumatic Diseases , involved reports on patients from investigators across 25 countries.

Key Points: 
  • The findings, published in the Annals of the Rheumatic Diseases , involved reports on patients from investigators across 25 countries.
  • The Arthritis Foundation estimates there are nearly 300,000 children and teens with arthritis in the United States.
  • Researchers found that less than 10% of pediatric patients with rheumatic diseases who were diagnosed with COVID-19 required hospitalization.
  • Childhood-onset rheumatic diseases include different types of arthritis and other rheumatic and inflammatory diseases that develop in children and teens.

Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Retrieved on: 
Thursday, March 17, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Private Securities Litigation Reform Act, SLE, Autoimmunity, Research, AbbVie, MD, Association, Technology, Securities Exchange Act of 1934, Twitter, ASCO, American College, Securities Act of 1933, Pembrolizumab, Security (finance), Arthritis, Scleroderma, American Association, Achievement, NEON, Annual general meeting, U.S. Securities and Exchange Commission, European Alliance, Rheumatology, NASDAQ, Investment, Forward-looking statement, Growth, Protein engineering, Merck & Co., ALPN, AACR, Synergy, National Institute, Medical research, Inflammation, Society, Federal Lands Jobs and Energy Security Act, Patient, Merck, Partnership, Private law, Company, Exercise, LinkedIn, Option, Arthritis Research & Therapy, American Society of Clinical Oncology, INSERM, Cancer, PIPE, Safety, COVID-19, Nature, Pharmaceutical industry, Vaccine, Animal, Horizon, Alpine

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2021.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2021.
  • Collaboration revenue for the fourth quarter ended December 31, 2021 was $4.5 million compared to $5.6 million for the fourth quarter ended December 31, 2020.
  • General and administrative expenses for the fourth quarter ended December 31, 2021 were $4.5 million compared to $3.0 million for the fourth quarter ended December 31, 2020.
  • NEON-1, NEON-2, "Synergy," and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.

SURVEY: Autoimmune Patients Lack Clear Information on COVID-19 Risks, Vaccination

Retrieved on: 
Wednesday, March 16, 2022
Confusion, Rheumatoid arthritis, Autoimmunity, Multiple sclerosis, Patient, Immunodeficiency, Lupus, Organization, Risk, COVID-19, European Alliance, Government, Degenerative disease, Scleroderma, Ensuring Patient Access and Effective Drug Enforcement Act, Pemphigus, Immune system, COVID-19 vaccine, Vaccination, Graves' disease, Pharmaceutical industry, Vaccine

LONDON, March 16, 2022 /PRNewswire/ -- A survey report released today by the nonprofit European Alliance for Patient Access reveals that, two years into the pandemic, autoimmune patients still don't have the necessary information to make informed decisions about COVID-19 vaccination. The online survey captured responses from 400 people living in Germany, France, U.K., Italy and Spain who have an autoimmune condition such as rheumatoid arthritis, lupus, multiple sclerosis, systemic sclerosis, pemphigus or Graves' disease.  

Key Points: 
  • Some medications for autoimmune diseases suppress the immune system, leaving patients with a higher risk of developing severe COVID-19 or breakthrough cases.Survey questions about COVID-19, risk awareness and vaccination revealed that autoimmune patients need health information tailored to their specific condition and the medication they take to manage it.
  • Patients reported confusion on various vaccination topics, and their responses identified a clear need for customized information.
  • While 81% of patients said they knew someone who contracted COVID-19, they did not necessarily recognize the full extent of their own vulnerability.
  • Many reported wanting policymakers to provide clear, correct and concise information that is centrally located and tailored to individual conditions and medications.